TORNTPHARM:NSE-Torrent Pharmaceuticals Limited (INR)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSE

Last Closing Price

INR 1,573.70

Change

+33.75 (+2.19)%

Market Cap

INR 529.33B

Volume

0.71M

Avg Analyst Target

INR 2,287.14 (+45.34%)

Avg User Target

INR
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


TORNTPHARM Stock Forecast & Price:
Based on the Torrent Pharmaceuticals Limited stock forecasts from 3 analysts, the average analyst target price for Torrent Pharmaceuticals Limited is INR 2,287.14 over the next 12 months. Torrent Pharmaceuticals Limited’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Torrent Pharmaceuticals Limited is Slightly Bearish, which is based on 6 positive signals and 8 negative signals. At the last closing, Torrent Pharmaceuticals Limited’s stock price was INR 1,573.70. Torrent Pharmaceuticals Limited’s stock price has changed by +1.20% over the past week, +3.67% over the past month and +6.52% over the last year.

About Torrent Pharmaceuticals Limited (TORNTPHARM:NSE)

Torrent Pharmaceuticals Limited engages in the research, development, manufacturing, and marketing of generic pharmaceutical formulations in India, the United States, Germany, Brazil, and internationally. It offers products in various therapeutic areas, including cardiovascular, ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-08-16 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
SUNPHARMA:NSE Sun Pharmaceutical Industries ..

+1.15 (+0.13%)

INR2,191.67B 56.39 28.48
DIVISLAB:NSE Divi's Laboratories Limited

+5.80 (+0.16%)

INR992.46B 33.52 25.55
DRREDDY:NSE Dr. Reddy's Laboratories Limit..

+37.00 (+0.87%)

INR714.00B 24.06 13.26
PEL:NSE Piramal Enterprises Limited

+5.35 (+0.28%)

INR455.79B 24.34 12.25
ALKEM:NSE Alkem Laboratories Limited

-9.60 (-0.32%)

INR353.08B 27.05 20.35
AUROPHARMA:NSE Aurobindo Pharma Limited

-9.45 (-1.59%)

INR343.04B 12.96 7.98
LUPIN:NSE Lupin Limited

+0.70 (+0.10%)

INR309.20B 25.10 -92.56
LAURUSLABS:NSE Laurus Labs Limited

+11.15 (+1.97%)

INR308.82B 37.01 21.64
IPCALAB:NSE IPCA Laboratories Limited

-2.10 (-0.23%)

INR235.87B 32.74 20.48
AJANTPHARM:NSE Ajanta Pharma Limited

-1.85 (-0.14%)

INR162.81B 22.86 15.33

ETFs Containing TORNTPHARM

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -4.00% 87% B+ 54% F
Dividend Return 1.22% 97% A+ 62% D-
Total Return -2.78% 84% B 54% F
Trailing 12 Months  
Capital Gain 4.31% 91% A- 50% F
Dividend Return 1.33% 85% B 62% D-
Total Return 5.63% 91% A- 50% F
Trailing 5 Years  
Capital Gain 139.95% 77% C+ 80% B-
Dividend Return 8.08% 90% A- 78% C+
Total Return 148.03% 77% C+ 80% B-
Average Annual (5 Year Horizon)  
Capital Gain 22.77% 57% F 60% D-
Dividend Return 0.92% 85% B 61% D-
Total Return 23.69% 57% F 61% D-
Risk Return Profile  
Volatility (Standard Deviation) 19.92% 95% A 96% A
Risk Adjusted Return 118.93% 97% A+ 99% A+
Market Capitalization 529.33B 96% A 95% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 66.13 9% F 14% F
Price/Book Ratio 8.76 12% F 10% F
Price / Cash Flow Ratio 29.36 32% F 23% F
EV/EBITDA 25.67 15% F 18% F
Management Effectiveness  
Return on Equity 13.18% 57% F 58% F
Return on Invested Capital 8.59% 50% F 55% F
Return on Assets 8.14% 68% D+ 75% C
Debt to Equity Ratio 35.66% 15% F 30% F
Technical Ratios  
Dividend Yield 1.07% 65% D 55% F
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.27 89% B+ 90% A-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector